Global Thyroid Cancer Drugs Market Size By Drug Type (Cabozantinib-S-Malate, Doxorubicin Hydrochloride), By Treatment (Medication, Chemotherapy), By End-User (Hospitals, Homecare), By Geographic Scope And Forecast

Thyroid Cancer Drugs Market Valuation – 2024-2031

Advances in diagnostic technologies are transforming healthcare by allowing for earlier and more precise detection of numerous illnesses. These cutting-edge techniques permit healthcare providers to spot diseases in their embryonic stages, frequently before symptoms appear fully. Thus, the technological advancements in the healthcare sector are driving the market size to surpass USD 833.84 Million in 2024 to reach a valuation of USD 2931.99 Million by 2031.

Personalized medicine and targeted treatment strategies are paradigm shifts in the medical community; rather than broad approaches, personalized medicine tailors treatments to individual patients based on their genetic makeup, lifestyle factors, and specific disease characteristics. Thus, the customized medication is enabling the market to grow at a CAGR of 17.02% from 2024 to 2031.

Thyroid Cancer Drugs MarketDefinition/ Overview

Thyroid cancer treatments are pharmaceuticals designed particularly to treat or manage various stages and forms of thyroid cancer. They are separate from drugs used to control thyroid hormone levels in cases of hyperthyroidism or hypothyroidism (non-cancerous disorders). Thyroid cancer drugs differ in various categories such as radioactive iodine (RAI), thyroid hormone therapy, targeted therapies, and chemotherapy.

Thyroid cancer treatments may include thyroid hormone replacement medication (such as levothyroxine) to replace hormones lost during thyroidectomy (surgical removal of the thyroid gland) or radioactive iodine therapy to kill any remaining thyroid tissue or cancer cells following surgery. Other drugs, such as tyrosine kinase inhibitors, may be used to treat advanced or metastatic thyroid cancer by inhibiting cancer cell growth. The type and stage of thyroid cancer will determine the best course of treatment. Your doctor will evaluate a variety of variables before recommending medication. Understanding the many thyroid cancer medicines available might help you feel more empowered to make healthcare decisions and collaborate with your doctor to achieve the best possible results.

With ongoing research, development, and a focus on customized medicine, we can anticipate a future with more effective and accessible treatment choices, resulting in better patient outcomes and a brighter future for people battling thyroid cancer. Research and development in targeted medicines will continue to thrive. We should expect increasingly more precise medications, with fewer side effects, that target specific mutations and cancer subtypes.Advances in immunotherapy, which uses the body’s immune system to attack cancer, have enormous implications for future treatment strategies.

How the Increasing Prevalence of Thyroid Cancer Globally is Escalating the Growth of the Thyroid Cancer Drugs Market?

The increasing prevalence of thyroid cancer patients is driving the growth of the thyroid cancer drugs market and is expected to continue its growth throughout the forecast period thanks to the growing healthcare infrastructure in the regions. For instance, in the in 2020, around 951,193 cases were registered of thyroid cancer. The annual rate of new thyroid cancer diagnoses was 13.9 per 100,000 men and women. The death rate was 0.5 per 100,000 men and women each year. These rates are age-adjusted and take into account cases and deaths from 2016 to 2020.

Pharmaceutical companies are currently pursuing novel drugs, with a particular emphasis on targeted therapeutics designed for advanced thyroid cancer treatment. These innovative medications represent a considerable step forward from existing therapy, allowing for more precise targeting of cancer cells while potentially minimizing side effects. This concentrated effort by pharmaceutical corporations highlights the changing environment of cancer treatment, in which precision medicine approaches are becoming increasingly important. These improvements not only promise to improve patient outcomes but also represent a shift toward more customized and targeted therapies in the fight against advanced thyroid cancer.

Increased healthcare expenditure and government initiatives are allowing the thyroid cancer drugs market to accelerate and sustain expansion during the forecast period. As global healthcare budgets continue to grow, there is a noticeable increase in funding allocated to the development and implementation of cutting-edge technologies and therapies for a wide range of disorders, including thyroid cancer. For instance, the Indian government has allocated around 1068.49 million for the Welfare in the 2024-24 budget. This increase in investment shows a rising understanding of the necessity of addressing healthcare concerns through innovative solutions.

The escalating prevalence of neuroendocrine tumors globally is fueling the growth of the thyroid cancer drugs market. Neuroendocrine tumor occurs in the thyroid glands, gastrointestinal tract (67.5%) bronchopulmonary tree (25.3%), small intestine (41.8%), rectum (27.4%), and stomach (8.7%). In in 2020 26,607 neuroendocrine tumor patients were diagnosed. Thus, the rising prevalence of neuroendocrine tumors is driving the growth of thyroid cancer drugs. In addition, the growing geriatric population has also contributed to its growth in recent times. Thyroid cancer is mostly diagnosed among people aged 55 to 64. For instance, according to the in the United States in 2020, the cases registered for thyroid cancer above the age of 50 are 45-55 (20.6%), 55-64 (20.7%), 65-74 (15.2%), 75-84 (5.7%), above 84 (1.3%).

How the High Cost Associated with the Thyroid Cancer Treatment and Side Effects after the Surgery are Hampering the Growth of the Thyroid Cancer Drugs Market?

High costs associated with the treatment of cancer are impeding the growth of the thyroid cancer drugs market. The several treatments and surgeries have high costs for the patient to treat, and the lower middle-class people are not able to afford the treatment. Emerging countries and underdeveloped nations are not able to afford the high-quality equipment, medications, and professionals in the country which is increasing the mortality rate for cancer and hampering the thyroid cancer drugs market. The cost of thyroid cancer ranges from USD 1425 to USD 17000 in the , and the rates of patients reported with the financial burden are estimated to be 16% to 50%.

The side effects attributed to thyroid cancer treatment are hampering the growth of the thyroid cancer drugs market. Thyroid cancer drugs, such as targeted therapies and hormone replacement pharmaceuticals, can have a variety of side effects. These could include nausea, exhaustion, diarrhea, skin sensitivities, blood pressure fluctuations, and hormone imbalances. While some side effects are minor and treatable, some can be severe and impair quality of life. Some thyroid cancer treatments may have unknown or long-term consequences for organ function, fertility, and overall health. Long-term monitoring and follow-up care are critical for detecting and managing any late-onset problems or side effects of treatment. The Radioactive iodine treatment is attributed to the high risk of DTC in the patients.

Thyroid cancer treatments, such as surgery or radioactive iodine therapy, can disrupt thyroid function, resulting in hypothyroidism or hyperthyroidism. As a result, patients may require continuing hormone replacement therapy to balance their thyroid hormones and manage the resulting symptoms. This lifetime medication is critical for maintaining hormonal balance and overall health, as thyroid dysfunction can affect metabolism, energy levels, mood, and other physical functions. Close monitoring and regular check-ins with healthcare providers are required to optimize hormone levels and reduce the impact of thyroid dysfunction on patients’ quality of life.

Category-Wise Acumens

How the Targeted Multiple Pathways of Vandetanib Drug is Enabling the Vandetanib Segment to Dominate Thyroid Cancer Drugs Market?

The Vandetanib segment showing dominance in the drug type category in the thyroid cancer drugs market thanks to the targeted multiple pathways and efficiency. Vandetanib inhibits numerous important biological signaling pathways involved in tumor growth and dissemination. This comprises the RET, VEGFR, and EGFR receptors. This multi-pronged approach may be more effective in limiting cancer cell proliferation.

Clinical trials have demonstrated that Vandetanib improves progression-free survival (PFS) in MTC patients compared to placebo. PFS is the amount of time a patient survives without their cancer deteriorating. Vandetanib is a targeted therapy, which means that it targets cancer cells while causing minimal damage to healthy cells when compared to standard chemotherapy. This can result in fewer adverse effects and potentially greater quality of life for patients.

Vandetanib is a convenient alternative for people receiving thyroid cancer treatment because it is administered orally once a day. This reduced dosing schedule increases treatment adherence since patients can easily incorporate the medicine into their everyday routine, eliminating the need for frequent clinic visits or difficult administration procedures.

Furthermore, Vandetanib has the potential to be used in combination therapy techniques for thyroid cancer. By combining Vandetanib with other treatments like surgery or radioactive iodine ablation, healthcare practitioners can take a more thorough and multifaceted approach to disease management. This combination therapy technique promotes synergistic effects by targeting cancer cells through various mechanisms of action, potentially increasing therapeutic efficacy.

How the Minimally Invasive Procedure and the Complete Cure of Thyroid Cancer by Surgery is Surging the Growth of Surgery Segment in the Thyroid Cancer Drugs Market?

The surgery segment is substantially growing in the treatment category and fueling the growth of the thyroid cancer drugs market. Surgery provides the chance of a complete cure for thyroid cancer, particularly for the most prevalent kinds, papillary and follicular carcinoma. By eliminating the malignant tissue, the likelihood of recurrence is greatly reduced.Advances in surgical methods have resulted in the development of minimally invasive treatments such as laparoscopic thyroidectomy. This decreases scarring, shortens hospital stays, and provides a shorter recovery period than typical open surgery. The cost of surgery for thyroid cancer in is USD 950 to USD 3,400 depending on the complexity and chosen hospital. After the surgery, the patients required radioactive iodine therapy to destroy the remaining cancer cells which cost USD 270 to USD 680.

Surgery is an important step once a suspicious thyroid nodule or growth has been detected through biopsy and imaging studies. Early surgical intervention is critical for improving the chances of a favorable outcome in thyroid cancer treatment. The primary goal of surgery is to fully remove the diseased tissue, reducing the number of leftover cancer cells that could cause recurrence later on. By removing the entire malignant mass, surgeons hope to eliminate the disease’s cause and limit the danger of regrowth or spread.

Surgery also serves an important diagnostic role by allowing the investigation of nearby lymph nodes for evidence of cancer spread. This intraoperative assessment gives useful information about the level of malignancy involvement and aids in determining the disease’s stage. Identifying lymph node metastases during surgery allows healthcare practitioners to adapt future treatment plans accordingly, such as proposing additional therapies such as radioactive iodine ablation or targeted therapy to attack any remaining cancer cells and prevent disease development.

Gain Access to Thyroid Cancer Drugs Market Report Methodology

Country/Region-wise Acumens

How the Rising Prevalence of Thyroid Cancer in the United States is Driving the Growth of the Thyroid Cancer Drugs Market?

North America holds the highest market share in the Thyroid Cancer Drugs Market and is expected to continue its growth throughout the forecast period thanks to the rising prevalence of thyroid cancer cases in the region. In the United States, thyroid cancer ranks as the 13th most frequently diagnosed cancer, with nearly 44,000 new cases estimated in 2022, representing approximately 2.3% of all cancer diagnoses. Among women, it stands as the 6th most commonly diagnosed cancer. Currently, the statistical likelihood of being diagnosed with thyroid cancer during their lifetime is one in 55 for women and one in 149 for men in the U.S.

This increase in thyroid cancer diagnoses coincides with a rise in radiation exposure within the general population, particularly in the United States. This escalation is largely attributed to the widespread utilization of diagnostic imaging procedures, notably computed tomography (CT) scans. The prevalence of CT scans has surged in recent decades due to their effectiveness in diagnosing various medical conditions. In addition, the thyroid cancer cases in Canada in 2022 are estimated to be 6700 (17.1%) from males 1850 (9.4), and females 4800 (24.6).

Increased healthcare resources allow for more investment in cutting-edge therapies, such as new thyroid cancer medications. This increased financial support allows healthcare systems to devote resources to the study, development, and implementation of novel therapies, ultimately broadening the toolkit accessible to physicians and patients. For instance, the United States government-funded around USD 49 Billion in the in 202.

How the Increasing Healthcare Facilities and Rising Prevalence of Thyroid Cancer in the Region is Expected to Drive the Asia Pacific Thyroid Cancer Drugs Market During the Forecast Period?

Asia Pacific is expected to be the fastest-growing region in the thyroid cancer market during the forecast period, thanks to the rising prevalence of thyroid cancer in nations like China, and India. According to the of China in 2022 around 466,100 cases were registered of thyroid cancer. In 2020 the number of people aged 60 and up reached 253.88 million in 2019, accounting for 18.1% of the total mainland population. According to  research analysts, findings, the elderly are at a higher risk of TC incidence and mortality; this may help to explain why TC occurrence and death are on the rise among the elderly.

The increasing healthcare facilities in emerging countries such as India, China, and Japan. The cost of chemotherapy for thyroid cancer in for one cycle is USD 680 to USD 2,270. The cost of thyroid cancer therapy in India is much lower than in Western countries like the United States, Canada, and the United Kingdom. The cost savings are due to a variety of variables, including cheaper infrastructure expenses, lower labor costs, and a favorable exchange rate for international patients. For example, thyroid surgery in the United States might cost anywhere from $15,000 to $40,000, making the same procedure in India a more inexpensive option.

While cost is an important concern, patients also want to know that the quality of healthcare services in India meets worldwide standards. Indian hospitals and medical institutions have received certification from internationally recognized organizations such as the Joint Commission International (JCI) and the National Certification Board for Hospitals and Healthcare Providers (NABH). These accreditations guarantee that patients receive the same quality of care and safety as they would in their native country.

Competitive Landscape

The competitive landscape of the thyroid cancer drugs market is driven by a shared goalto develop effective, safe, and accessible treatment options for patients. This ongoing competition fosters innovation and holds promise for a future with better outcomes for those battling thyroid cancer. Smaller biotechnology companies and research organizations are aggressively creating new therapeutics, bringing innovation to market. These companies specialize in targeted medicines that have unique mechanisms of action. Antibody-drug conjugates (ADCs) are combinations of targeted therapy and cytotoxic payloads. Immunotherapy uses the body’s immune system to combat cancer.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the thyroid cancer drugs market include

• Mylan N.V.
• Bristol-Myers Squibb Company
• Teva Pharmaceutical Industries Ltd
• Jerome Stevens Pharmaceuticals, Inc
• Baxter
• Abbott
• Celgene Corporation
• AstraZeneca
• GlaxoSmithKline plc.

Thyroid Cancer Drug Latest Developments

• In August 2021, GlaxoSmithKline plc announced that the company received the FDA approval JEMPERLI (dostarlimab-gxly) is a programmed cell death receptor-1 (PD-1) blocking antibody used to treat adult patients with mismatch repair-deficient (dMMR) recurring or advanced solid tumors.

Report Scope

Thyroid Cancer Drugs Market, By Category

Drug

• Cabozantinib-S-Malate
• Doxorubicin Hydrochloride
• Ipilimumab
• Vandetanib
• Sorafenib

Treatment

• Medication
• Chemotherapy
• Radioactive iodine (radioiodine) therapy
• Hormone therapy
• Surgery

End-User

• Hospitals
• Homecare
• Specialty Clinics

Route of Administration

• Oral
• Injectable

Region

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our